Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
filingDate |
2016-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_313214e5a24a19aad3f0519cb4079446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47bfe6c01bda699bc4f589c83fe80a68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d135b52c3ff1d59ae820c28f63eb61e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2c59f6d17cc5520b8b4db816b56d1d0 |
publicationDate |
2019-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2019022063-A1 |
titleOfInvention |
New use |
abstract |
The present invention relates to methods and pharmaceutical compositions for reducing arterial stiffness in a human patient showing at least one symptom selected from increased pulse wave velocity (PWV) and increased pulse pressure (PP) comprising administration to said patient of a therapeutically effective amount or a prophylactically effective amount of a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme, in particular of a combination of sacubitril or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof in a 1:1 molar ratio. |
priorityDate |
2015-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |